Virtu Financial LLC raised its holdings in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 308.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,132 shares of the biotechnology company's stock after purchasing an additional 5,388 shares during the period. Virtu Financial LLC's holdings in Repligen were worth $907,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD boosted its stake in Repligen by 11.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock valued at $1,027,165,000 after purchasing an additional 743,815 shares during the last quarter. Point72 Asset Management L.P. boosted its stake in shares of Repligen by 183.1% in the 4th quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company's stock worth $132,227,000 after buying an additional 594,189 shares during the last quarter. Alyeska Investment Group L.P. purchased a new position in shares of Repligen in the 4th quarter worth $53,428,000. Raymond James Financial Inc. purchased a new position in shares of Repligen in the 4th quarter worth $52,492,000. Finally, Marshall Wace LLP boosted its stake in shares of Repligen by 73.8% in the 4th quarter. Marshall Wace LLP now owns 412,235 shares of the biotechnology company's stock worth $59,337,000 after buying an additional 175,013 shares during the last quarter. Institutional investors own 97.64% of the company's stock.
Insider Activity
In related news, Director Martin D. Madaus acquired 1,800 shares of the firm's stock in a transaction dated Friday, August 8th. The stock was acquired at an average price of $112.13 per share, with a total value of $201,834.00. Following the acquisition, the director directly owned 1,800 shares in the company, valued at $201,834. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 1.20% of the stock is currently owned by company insiders.
Repligen Trading Down 1.4%
Shares of RGEN stock traded down $1.82 on Friday, reaching $124.82. 427,019 shares of the company's stock were exchanged, compared to its average volume of 781,060. Repligen Corporation has a 52 week low of $102.96 and a 52 week high of $182.52. The company has a current ratio of 8.59, a quick ratio of 7.32 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $7.02 billion, a PE ratio of -499.27, a P/E/G ratio of 2.34 and a beta of 1.05. The company's fifty day simple moving average is $122.58 and its 200 day simple moving average is $133.33.
Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The firm had revenue of $182.37 million for the quarter, compared to the consensus estimate of $174.62 million. During the same period last year, the firm earned $0.40 earnings per share. The company's revenue for the quarter was up 14.8% on a year-over-year basis. As a group, analysts forecast that Repligen Corporation will post 1.72 EPS for the current year.
Analyst Upgrades and Downgrades
A number of brokerages recently commented on RGEN. Wells Fargo & Company decreased their target price on Repligen from $180.00 to $175.00 and set an "overweight" rating on the stock in a report on Wednesday, July 30th. Barclays began coverage on Repligen in a report on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 target price on the stock. Royal Bank Of Canada raised their target price on Repligen from $193.00 to $204.00 and gave the stock an "outperform" rating in a report on Wednesday, July 30th. Wall Street Zen downgraded Repligen from a "buy" rating to a "hold" rating in a research report on Sunday, June 29th. Finally, Evercore ISI cut their target price on Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a research report on Tuesday, July 8th. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $169.45.
View Our Latest Report on RGEN
About Repligen
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Read More

Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.